Silo Wellness Inc.

Silo Wellness Inc., a psychedelics and wellness company, develops psychedelic medicine to reduce trauma. It develops and sells psilocybin-free functional mushroom tinctures; and the formulation of a psilocybin nasal spray in Jamaica. It also offers a portfolio of functional mushroom products: Jamaican and Oregon psychedelic wellness retreats, as well as cultivates psychedelic mushrooms and truffles in Jamaica; and develops bricks and mortar smart shop in Jamaica. The company was formerly known as Yukoterre Resources Inc. and changed its name to Silo Wellness Inc. February 26, 2021. Silo Wellness Inc. is headquartered in Toronto, Canada.

Silo Wellness Inc. trades as SILO.CN on CNQ. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in CAD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $335,811 of revenue and -$5.81M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Silo Wellness Inc. can be compared against peers such as Canada House Cannabis Group Inc., BC Craft Supply Co. Ltd., Delta 9 Cannabis Inc., Entourage Health Corp., New Leaf Ventures Inc, Orchid Ventures, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $1.54M, beta of 0.76, and return on equity of +109.6%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

SILO.CN currently shows total debt of $33,478 and beta of 0.76. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.silowellness.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.